Venetoclax (ABT‐199), a small‐molecule inhibitor selectively targeting BCL‐2, has been approved by more than 50 countries for the treatment of adult chronic lymphocytic leukaemia (CLL) [12]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.